Document is current
Any future updates will be listed below
-
Authors
Gew, Jessie https://orcid.org/0000-0001-7816-4927
Hyder, Yousef F.
Grech, Olivia https://orcid.org/0000-0001-5560-802X
Brunstetter, Tyson
Tarver, William
Mason, Sara S.
Gibson, C. Robert https://orcid.org/0000-0001-9422-3130
Polk, James D.
Schneider, Victor S.
van Baalen, Mary
Mitchell, James L.
Yiangou, Andreas https://orcid.org/0000-0001-8905-5734
Mollan, Susan P.
Sinclair, Alexandra J. https://orcid.org/0000-0003-2777-5132
-
Funding
Funding for this research was provided by:
Sir Jules Thorn Charitable Trust
DH | National Institute for Health Research
UK Space Agency
- License Information
-
More Information
Article History
Received: 30 December 2025
Revised: 29 April 2026
Accepted: 12 June 2026
First Online: 30 June 2026
Competing interests
: Jessie Gew reports no conflicts. Yousef Hyder reports no conflicts. Olivia Grech reports consultancy fees (Invex Therapeutics). Tyson Brunstetter reports no conflicts. William Tarver reports no conflicts. Sara Mason reports no conflicts. Robert Gibson reports no conflicts. James D Polk reports no conflicts. Victor Schneider reports no conflicts. Mary Van Baalen reports no conflicts. James Mitchell is employed by the Ministry of Defense, UK. Andreas Yiangou reports speaker fees from Teva UK. Susan Mollan reports consultancy fees (Invex Therapeutics); advisory board fees (Ocular Therapeutix, Dompé); speaker fees (Teva, AbbVie); Travel (AbbVie, EssilorLuxottica, European Alliance of Associations for Rheumatology); Receipt of equipment (Heidelberg Engineering). Susan Mollan is a member of the Eye editorial board. Alexandra Sinclair reports she has consulted for Novartis, AbbVie, Vertex and Orion Pharma and speaker fees from Teva UK and Novartis on unrelated topics.
